Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
Salzano, Giuseppina
Wankar, Jitendra
Ottani, Stefano
Villemagne, Baptiste
Baulard, Alain R.
Willand, Nicolas
Brodin, Priscille
Manet, Ilse
Gref, Ruxandra
Baptiste Villemagne
Villemagne Baptiste
ORCID: 0000-0002-8416-5253
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches
10.1021/jm500422b
Unconventional surface plasmon resonance signals reveal quantitative inhibition of transcriptional repressor EthR by synthetic ligands
10.1016/j.ab.2014.02.011
Structural and docking studies of potent ethionamide boosters
10.1107/S0108270113028126
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200825u
Tuberculosis: The drug development pipeline at a glance
10.1016/j.ejmech.2012.02.033
A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR
10.1016/j.bbapap.2018.12.003
A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2.
10.1016/j.ejmech.2019.02.023
Intrinsic Antibacterial Activity of Nanoparticles Made of beta-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.
10.1021/acsnano.8b07902
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity
10.1021/acsinfecdis.9b00277
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections
10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism
10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria
10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis
10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis
10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters
10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization
10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin
10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection
10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1
10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo
10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges
10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis
10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system
10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays
10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches
10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways
10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings
10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis
10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence
10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis
10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200076a
High-content screening in infectious diseases
10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ
10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery
10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure
10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors
10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems
10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP
10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans
10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity
10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis
10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva
10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images
10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues
10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis
10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents
10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence
10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection
10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence
10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis
10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity
10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics
10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions
10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine
10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6
10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens
10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex
10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex
10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides
10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro
10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase
10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides
10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase
10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides
10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions
10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus
10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays
10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors
10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis
10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation
10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis
10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase
10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening
10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections
10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation
10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters
10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis
10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells
10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria
10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation
10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies.
10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.
10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis.
10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Worms' Antimicrobial Peptides.
10.3390/md17090512
T(oo)bAd.
10.1038/s41589-019-0347-x
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Cell microbiology interview
10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts
10.1099/mgen.0.000505
willand nicolas
nicolas willand
ORCID: 0000-0002-0784-0462
Neuraminidase inhibitors and risk of H5 N1 influenza,Les inhibiteurs de neuraminidase face au risque de grippe aviaire
10.1016/s0003-4509(07)90016-4
Unconventional surface plasmon resonance signals reveal quantitative inhibition of transcriptional repressor EthR by synthetic ligands
10.1016/j.ab.2014.02.011
Water-based conditions for the microscale parallel synthesis of bicyclic lactams
10.1016/j.tetlet.2012.11.082
Exploring drug target flexibility using in situ click chemistry: Application to a mycobacterial transcriptional regulator
10.1021/cb100177g
Synthesis of N-(iodophenyl)-amides via an unprecedented Ullmann-Finkelstein tandem reaction
10.1016/j.tetlet.2005.12.022
Synthesis of functionalized 2-isoxazolines as three-dimensional fragments for fragment-based drug discovery
10.1016/j.tetlet.2015.05.035
Efficient, two-step synthesis of N-substituted nortropinone derivatives
10.1016/j.tetlet.2007.05.110
Natural compounds: Leads or ideas? Bioinspired molecules for drug discovery
10.1111/j.1747-0285.2008.00673.x
MALDI imaging techniques dedicated to drug-distribution studies
10.4155/bio.11.88
Solid and solution phase syntheses of the 2-cyanopyrrolidide DPP-IV inhibitor NVP-DPP728
10.1016/S0040-4020(02)00536-7
Original loading and Suzuki conditions for the solid-phase synthesis of biphenyltetrazoles. Application to the first solid-phase synthesis of irbesartan
10.1016/j.tetlet.2008.02.147
Application of Ullmann and Ullmann-Finkelstein reactions for the synthesis of N-aryl-N-(1H-pyrazol-3-yl) acetamide or N-(1-aryl-1H-pyrazol-3-yl) acetamide derivatives and pharmacological evaluation
10.1016/j.ejmech.2011.05.056
A simple reaction to produce small structurally complex and diverse molecules
10.1016/j.tetlet.2004.05.008
Efficient, protection-free Suzuki-Miyaura synthesis of ortho- biphenyltetrazoles
10.1016/j.tetlet.2005.07.082
Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands
10.1093/nar/gkr1113
Microwave-assisted synthesis of functionalized spirohydantoins as 3-D privileged fragments for scouting the chemical space
10.1016/j.tetlet.2016.05.065
Ethionamide boosters: Synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors
10.1021/jm200076a
Carbohydrate-protein interactions at interfaces: Synthesis of thiolactosyl glycolipids and design of a working model for surface plasmon resonance
10.1039/b210672h
Structural and docking studies of potent ethionamide boosters
10.1107/S0108270113028126
A versatile solid-phase synthesis of 3-aryl-1,2,4-oxadiazolones and analogues
10.1016/j.tetlet.2006.12.050
UFU ('Ullmann-Finkelstein-Ullmann'): a new multicomponent reaction
10.1016/j.tetlet.2006.04.041
Palladium-free Sonogashira-type cross-coupling reaction of bromoisoxazolines or N-alkoxyimidoyl bromides and alkynes
10.1016/j.tetlet.2016.01.070
Tuberculosis: The drug development pipeline at a glance
10.1016/j.ejmech.2012.02.033
Synthesis and structural studies of a novel scaffold for drug discovery: A 4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4′-piperidine]
10.1016/j.tetlet.2003.11.079
Synthetic EthR inhibitors boost antituberculous activity of ethionamide
10.1038/nm.1950
A facile and rapid synthesis of N-benzyl-2-substituted piperazines
10.1016/j.tetlet.2011.02.011
Ligand efficiency driven design of new inhibitors of mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches
10.1021/jm500422b
Discovery of novel N -phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis
10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors
10.1021/jm200825u
A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR
10.1016/j.bbapap.2018.12.003
A novel codrug made of the combination of ethionamide and its potentiating booster: Synthesis, self-assembly into nanoparticles and antimycobacterial evaluation
10.1039/c9ob00680j
Structural analysis of the interaction between spiroisoxazoline SMARt-420 and the Mycobacterium tuberculosis repressor EthR2
10.1016/j.bbrc.2017.04.074
Recent advances in the design of inhibitors of mycobacterial transcriptional regulators to boost thioamides anti-tubercular activity and circumvent acquired-resistance
10.1016/bs.armc.2019.06.003
New active leads for tuberculosis booster drugs by structure-based drug discovery
10.1039/c7ob00910k
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
10.1126/science.aag1006
Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis
10.1016/j.ejmech.2018.09.038
Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis
10.1021/acsnano.8b07902
Combination therapy for tuberculosis treatment: Pulmonary administration of ethionamide and booster co-loaded nanoparticles
10.1038/s41598-017-05453-3
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity
10.1021/acsinfecdis.9b00277
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening
10.1016/j.ejmech.2020.112440
Microwave-Assisted Suzuki-Miyaura Cross Coupling using Nickel as Catalyst to Rapidly Access to 3-Arylazetidine
10.1002/slct.201702101
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
A fragment-based approach towards the discovery of N-substituted tropinones as inhibitors of Mycobacterium tuberculosis transcriptional regulator EthR2
10.1016/j.ejmech.2019.02.023
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton.
10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling.
10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone.
10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection.
10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection.
10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis.
10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening.
10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces.
10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR.
10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce.
10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens.
10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water.
10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries.
10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment.
10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables.
10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system.
10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis.
10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids.
10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.
10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages.
10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis.
10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs.
10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis.
10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections.
10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.
10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.
10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization.
10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro.
10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin].
10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.
10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo.
10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges].
10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays.
10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways.
10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.
10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence.
10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings.
10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
10.1371/journal.pone.0026675
High-content screening in infectious diseases.
10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling.
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ.
10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems.
10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure.
10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.
10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity.
10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans].
10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis.
10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva.
10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence.
10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents.
10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence.
10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine.
10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity.
10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics.
10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6.
10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex.
10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family.
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.
10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.
10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant.
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides.
10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Jitendra Wankar
Wankar Jitendra
ORCID: 0000-0002-0916-0524
Widening the Therapeutic Perspectives of Clofazimine by Its Loading in Sulfobutylether β-Cyclodextrin Nanocarriers: Nanomolar IC50 Values against MDR S. epidermidis
10.1021/acs.molpharmaceut.8b00321
Photoactivity of New Octacationic Magnesium(II) and Zinc(II) Porphyrazines in a Water Solution and G-Quadruplex Binding Ability of Differently Sized Zinc(II) Porphyrazines
10.1021/acs.inorgchem.7b01557
Mesoporous silica particles as a lipophilic drug vehicle investigated by fluorescence lifetime imaging
10.1039/c7tb00198c
Efficient loading of ethionamide in cyclodextrin-based carriers offers enhanced solubility and inhibition of drug crystallization
10.1016/j.ijpharm.2017.05.041
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Recent Advances in Host–Guest Self‐Assembled Cyclodextrin Carriers: Implications for Responsive Drug Delivery and Biomedical Engineering
10.1002/adfm.201909049
Rutin nanosuspension for potential management of osteoporosis: effect of particle size reduction on oral bioavailability, in vitro and in vivo activity
10.1080/10837450.2020.1765378
Ilse Gert Julia Manet
Manet Ilse Gert Julia
/ Ilse Manet
/ Ilse Gert Julia Manet
ORCID: 0000-0002-8789-358X
Email: ilse.manet@isof.cnr.it
Chemical design enables the control of conformational polymorphism in functional 2,3-thieno(bis)imide-ended materials
10.1039/c4cc09177a
Synergic effect of unsaturated inner bridges and polymorphism for tuning the optoelectronic properties of 2,3-thieno(bis)imide based materials
10.1039/c4tc01792g
Fluorescent cyclodextrin carriers for a water soluble ZnII pyrazinoporphyrazine octacation with photosensitizer potential
10.1039/c3ra47034b
Host–Guest Interactions in Fe(III)-Trimesate MOF Nanoparticles Loaded with Doxorubicin
10.1021/jp503809w
Photophysics and ex vivo biodistribution of β-cyclodextrin-meso- tetra(m-hydroxyphenyl)porphyrin conjugate for biomedical applications
10.1039/c4pp00088a
Supramolecular photochemistry of drugs in biomolecular environments
10.1039/c3cs60402k
"click" on MOFs: A versatile tool for the multimodal derivatization of N3-decorated metal organic frameworks
10.1021/cm400899a
A Fluorine 1,2-Migration via Aryl Cation/Radical/Radical Anion/Radical Sequence
10.1021/ol401670p
A time-temperature integrator based on fluorescent and polymorphic compounds
10.1038/srep02581
An engineered nanoplatform for bimodal anticancer phototherapy with dual-color fluorescence detection of sensitizers
10.1039/c3cc40714d
Citric acid-γ-cyclodextrin crosslinked oligomers as carriers for doxorubicin delivery
10.1039/c3pp50169h
Unravelling molecular mechanisms in the fluorescence spectra of doxorubicin in aqueous solution by femtosecond fluorescence spectroscopy
10.1039/c2cp44056c
Water-Soluble Naphthalene Diimides as Singlet Oxygen Sensitizers
10.1021/jo401347z
A close-up on doxorubicin binding to γ-cyclodextrin: An elucidating spectroscopic, photophysical and conformational study
10.1039/c2ra01221a
Graphene-organic hybrids as processable, tunable platforms for pH-dependent photoemission, obtained by a new modular approach
10.1039/c2jm33349j
Optical properties of hybrid T3Pyr/SiO2/3C-SiC nanowires
10.1186/1556-276x-7-680
Self-assembly and electrical properties of a novel heptameric thiophene-benzothiadiazole based architectures
10.1039/c2cc36510c
β-Cyclodextrin polymer nanoparticles as carriers for doxorubicin and artemisinin: A spectroscopic and photophysical study
10.1039/c2pp25014d
A cationic ZnII porphyrazine induces a stable parallel G-quadruplex conformation in human telomeric DNA
10.1039/c0ob00598c
Affinity of the anthracycline antitumor drugs Doxorubicin and Sabarubicin for human telomeric G-quadruplex structures
10.1039/c0cp00898b
Combination of spectroscopic and computational methods to get an understanding of supramolecular chemistry of drugs: from simple host systems to biomolecules
10.1039/c1cp21992h
Complexes of the antitumoral drugs Doxorubicin and Sabarubicin with telomeric G-quadruplex in basket conformation: ground and excited state properties
10.1039/c1pp05065f
Poly(lactic acid) as a transparent matrix for luminescent solar concentrators: a renewable material for a renewable energy technology
10.1039/c1ee01391b
Stereoselective interaction of ketoprofen enantiomers with β-cyclodextrin: Ground state binding and photochemistry
10.1039/c0pp00262c
Tetra-2,3-pyrazinoporphyrazines with Externally Appended Pyridine Rings. 10. A Water-Soluble Bimetallic (Zn-II/Pt-II) Porphyrazine Hexacation as Potential Plurimodal Agent for Cancer Therapy: Exploring the Behavior as Ligand of Telomeric DNA G-Quadruplex Structures
10.1021/ic200514z
Tetra-2,3-pyrazinoporphyrazines with Externally Appended Pyridine Rings. 9. Novel Heterobimetallic Macrocycles and Related Hydrosoluble Hexacations as Potentially Active Photo/Chemotherapeutic Anticancer Agents
10.1021/ic200498s
Facile tuning from blue to white emission in silica nanoparticles doped with oligothiophene fluorophores
10.1039/c0jm01579b
Fluoroquinolones as potential photochemotherapeutic agents: covalent addition to guanosine monophosphate
10.1039/c0ob00056f
Chiral recognition of 2-(3-benzoylphenyl)propionic acid (ketoprofen) by serum albumin: an investigation with microcalorimetry, circular dichroism and molecular modelling
10.1039/b906021a
Inter-and intramolecular photochemical reactions of fleroxacin
10.1021/ol900189v
Licochalcone A bound to bovine serum albumin: a spectroscopic, photophysical and structural study
10.1039/b823227j
Gaining an insight into the photoreactivity of a drug in a protein environment: A case study on nalidixic acid and serum albumin
10.1021/jp711261n
Modeling the photochemistry of the reference phototoxic drug lomefloxacin by steady-state and time-resolved experiments, and DFT and post-HF calculations
10.1002/chem.200701099
Revealing phenylium, phenonium, vinylenephenonium, and benzenium ions in solution
10.1002/chem.200701043
Structure and properties of licochalcone A-human serum albumin complexes in solution: a spectroscopic, photophysical and computational approach to understand drug-protein interaction
10.1039/b809241a
Binding and photochemistry of enantiomeric 2-(3-benzoylphenyl)propionic acid (ketoprofen) in the human serum albumin environment
10.1039/b614163c
Photosensitized oxidation of sulfides: Discriminating between the singlet-oxygen mechanism and electron transfer involving superoxide anion or molecular oxygen
10.1002/chem.200501144
Aryl cation and carbene intermediates in the photodehalogenation of chlorophenols
10.1002/chem.200400681
Photochemical and structural properties of the cyclodextrin inclusion complexes of aryl-olefin bichromophores
10.1016/j.jphotochem.2005.04.014
Photoisomerization and photohydration of 3-hydroxystyrylnaphthalenes
10.1039/b505168a
The photochemistry of 4-chlorophenol in water revisited: The effect of cyclodextrins on cation and carbene reactions
10.1002/chem.200401227
Photocyclization of trans-1-(1′-naphthyl)-2-(3-hydroxyphenyl -ethene: Evidence for adiabatic 1trans*→ 1cis* photoisomerization
10.1039/b404308a
Gel-like lyomesophases formed in organic solvents by self-assembled guanine ribbons
10.1002/1521-3765(20020503)8:9<2143::aid-chem2143>3.0.co;2-g
2,2 '-bipyridine lariat calixcrowns: A new class of encapsulating ligands forming highly luminescent Eu3+ and Tb3+ complexes
10.1002/(sici)1521-3765(20000317)6:6<1026::aid-chem1026>3.0.co;2-c
Calix 4 arene podands and barrelands incorporating 2,2'-bipyridine moieties and their lanthanide complexes: Luminescence properties
10.1002/chem.19970031114
Luminescence of Eu3+ and Tb3+ complexes of new macrobicyclic ligands derived from p-tert-butylcalix 4 arene
10.1016/s0020-1693(96)05293-0
Synthesis of calix 4 arene receptors incorporating (2,2'-bipyridin-6-yl)methyl and (9-methyl-1,10-phenanthrolin-2-yl)methyl chromophores and luminescence of their Eu3+ and Tb3+ complexes
10.1039/p29960000395
Lanthanide complexes of cage-type ligands labels luminescent labels in fluoroimmunoassays
10.1117/12.208524
Lanthanide complexes of encapsulating ligands: Luminescent devices at the molecular level
10.1351/pac199567010135
LUMINESCENT EU3+ AND TB3+ COMPLEXES OF A BRANCHED MACROCYCLIC LIGAND INCORPORATING 2,2'-BIPYRIDINE IN THE MACROCYCLE AND PHOSPHINATE ESTERS IN THE SIDE ARMS
10.1002/anie.199415011
SYNTHESIS AND LUMINESCENCE OF LANTHANIDE COMPLEXES OF A BRANCHED MACROCYCLIC LIGAND CONTAINING 2,2'-BIPYRIDINE AND 9-METHYL-1,10-PHENANTHROLINE SUBUNITS
10.1021/ic00083a020
A naphthalene diimide dyad for fluorescence switch-on detection of G-quadruplexes
10.1039/c5cc01536g
Polymer nanoparticles with electrostatically loaded multicargo for combined cancer phototherapy
10.1039/c5tb00234f
Additive, modular functionalization of reactive self-assembled monolayers: Toward the fabrication of multilevel optical storage media
10.1039/c5nr00346f
A Hetero-Bifunctional Spacer for the Smart Engineering of Carbon-Based Nanostructures
10.1002/cplu.201402391
Scope and limitations of the TEMPO/EPR method for singlet oxygen detection: The misleading role of electron transfer
10.1016/j.freeradbiomed.2014.08.020
Pyrazinoporphyrazines with externally appended pyridine rings. 13. Structure, UV-visible spectral features, and noncovalent interaction with DNA of a positively charged binuclear (ZnII/PtII) macrocycle with multimodal anticancer potentialities
10.1021/ic3020755
Diastereoselectivity and site dependency in the photochemistry of ketoprofen in the bovine serum albumin matrix
10.1562/2005.07-11-RA-608
An ESI-MS and NMR study of the self-assembly of guanosine derivatives
10.1002/1522-2675(20010711)84:7<2096::AID-HLCA2096>3.0.CO;2-G
Chapter 154 Antenna effect in encapsulation complexes of lanthanide ions
10.1016/S0168-1273(96)23005-3
Light-Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells
10.1002/cmdc.201500396
Photoresponsive cyclodextrin nanosystems: design, structure and function
10.1039/9781782622772-00226
Self-protective action in multicomponent fluorescent self-assembled monolayers
10.1039/c5ra27454k
Ultrafast Electron Transfer in Complexes of Doxorubicin with Human Telomeric G-Quadruplexes and GC Duplexes Probed by Femtosecond Fluorescence Spectroscopy
10.1002/cphc.201501091
Zinc Coordination Polymers Containing the m-(2-thiazolyl)benzoic Acid Spacer: Synthesis, Characterization and Luminescent Properties in Aqueous Solutions
10.1002/slct.201600331
Dual luminescence in solid CuI(piperazine): hypothesis of an emissive 1-D delocalized excited state
10.1039/c5dt02204e
Metal-functionalized covalent organic frameworks as precursors of supercapacitive porous N-doped graphene
10.1039/c6ta09296a
Mesoporous silica particles as a lipophilic drug vehicle investigated by fluorescence lifetime imaging
10.1039/c7tb00198c
Cyclodextrin-based metal-organic frameworks particles as efficient carriers for lansoprazole: Study of morphology and chemical composition of individual particles
10.1016/j.ijpharm.2017.05.056
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Direct Irradiaton of Aryl Sulfides: Homolytic Fragmentation and Sensitized S-Oxidation
10.1021/acs.joc.7b01518
Efficient loading of ethionamide in cyclodextrin-based carriers offers enhanced solubility and inhibition of drug crystallization
10.1016/j.ijpharm.2017.05.041
Photoactivity of New Octacationic Magnesium(II) and Zinc(II) Porphyrazines in a Water Solution and G-Quadruplex Binding Ability of Differently Sized Zinc(II) Porphyrazines
10.1021/acs.inorgchem.7b01557
Widening the Therapeutic Perspectives of Clofazimine by Its Loading in Sulfobutylether β-Cyclodextrin Nanocarriers: Nanomolar IC50 Values against MDR S. epidermidis
10.1021/acs.molpharmaceut.8b00321
Immobilization of Perylene‐3,4,9,10‐Tetracarboxylic Dianhydride on Hollow Polysulfone Fibers: Primary Amine Coupling and Fluorescence Reporting
10.1002/cplu.201800681
Targeting the Bacterial Membrane with a New Polycyclic Privileged Structure: A Powerful Tool To Face Staphylococcus aureus Infections
10.1021/acsinfecdis.9b00072
Dyads of G‐Quadruplex Ligands Triggering DNA Damage Response and Tumour Cell Growth Inhibition at Subnanomolar Concentration
10.1002/chem.201900766
Rhodamine B hydrazide loaded polysulfone fabrics for Cu(II) detection: Morphological and optical properties
10.1002/app.48408
Cover Feature: Immobilization of Perylene‐3,4,9,10‐Tetracarboxylic Dianhydride on Hollow Polysulfone Fibers: Primary Amine Coupling and Fluorescence Reporting (ChemPlusChem 9/2019)
10.1002/cplu.201900432
Combined wet lithography and fractional precipitation as a tool for fabrication of spatially controlled nanostructures of poly(3-hexylthiophene) ordered aggregates
10.1039/C9NR10057A
Control of polymorphism in thiophene derivatives by sublimation-aided nanostructuring
10.1039/C9CC09507A
Cellulose Acetate Fabrics Loaded with Rhodamine B Hydrazide for Optical Detection of Cu(II)
10.3390/molecules25163751
Rubbing induced reversible fluorescence switching in thiophene-based organic semiconductor films by mechanical amorphisation
10.1039/D1TC01036K
Can mesoporous nanoparticles promote bioavailability of topical pharmaceutics?
10.1016/j.ijpharm.2021.120609
The Binding Pocket at the Interface of Multimeric Telomere G‐quadruplexes: Myth or Reality?
10.1002/chem.202101486
Improved eradication efficacy of a combination of newly identified antimicrobial agents in C. albicans and S. aureus mixed-species biofilm
10.1016/j.resmic.2021.103873
